Future directions in regional treatment strategies for melanoma and sarcoma.
Hyperthermic isolated limb perfusion (HILP) with melphalan and more recently isolated limb infusion (ILI) with melphalan +/- dactinomycin are common treatment modalities for both in-transit melanoma of the extremity and advanced extremity sarcoma. In order to further optimize treatment, future research should focus on selection of appropriate patients, verification of a technique that produces consistent results while maintaining acceptable toxicity, and development of novel strategies and agents. Development of these novel agents and strategies has potential to not only improve the efficacy of regional chemotherapy but may also help guide future strategies for systemic treatment.
Beasley
G M
GM
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Ross
M I
MI
Tyler
D S
DS
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods / Q000639:trends*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008207:Lymphatic Metastasis / Q000517:prevention & control; D008545:Melanoma / Q000188:drug therapy*; D008558:Melphalan / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy*
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan